Benzinga | May 17, 2021 12:36PM EDT

Novo Nordisk Says Ziltivekimab Reduced Inflammatory Biomarkers Associated With Atherosclerosis In People With Chronic Kidney Disease In Phase 2 Trial

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=59583